MOR News and Press, MorphoSys AG From 11/11/21

The following slide deck was published by MorphoSys AG in conjunction with their 2021 Q3 earnings call. For further details see: MorphoSys AG 2021 Q3 - Results - Earnings Call Presentation

Monjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-Q Ten abstracts, including two oral presentations, accepted at upcoming ASH Pelabresib data for arm 3 of MANIFEST study to be presented at ASH confirm prior data Felzartamab demonstrated ...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management Board effective December 31, 2021 to pu...

Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) presented interim results from the M-PLAC...

- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational data - MANIFEST update on pelabresib monotherapy in patients with myelofibrosis ...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to € 18.6 million (US$ 22 million) for the third quarter of 2021 and € 46.4 mil...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN). IgAN, also known as Berger's di...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for gantenerumab , an anti-amyloid beta antibody developed f...

-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union (...

- The decision by the European Commission is based on data from the L-MIND study evaluating Minjuvi in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Un...